136 related articles for article (PubMed ID: 16630566)
1. Interactions of recombinant prions with compounds of therapeutical significance.
Georgieva D; Schwark D; von Bergen M; Redecke L; Genov N; Betzel C
Biochem Biophys Res Commun; 2006 Jun; 344(2):463-70. PubMed ID: 16630566
[TBL] [Abstract][Full Text] [Related]
2. Preventing misfolding of the prion protein by trimethylamine N-oxide.
Bennion BJ; DeMarco ML; Daggett V
Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
[TBL] [Abstract][Full Text] [Related]
3. Expansion of the octarepeat domain alters the misfolding pathway but not the folding pathway of the prion protein.
Leliveld SR; Stitz L; Korth C
Biochemistry; 2008 Jun; 47(23):6267-78. PubMed ID: 18473442
[TBL] [Abstract][Full Text] [Related]
4. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro.
Tagliavini F; Forloni G; Colombo L; Rossi G; Girola L; Canciani B; Angeretti N; Giampaolo L; Peressini E; Awan T; De Gioia L; Ragg E; Bugiani O; Salmona M
J Mol Biol; 2000 Jul; 300(5):1309-22. PubMed ID: 10903871
[TBL] [Abstract][Full Text] [Related]
5. Molecular model of an alpha-helical prion protein dimer and its monomeric subunits as derived from chemical cross-linking and molecular modeling calculations.
Kaimann T; Metzger S; Kuhlmann K; Brandt B; Birkmann E; Höltje HD; Riesner D
J Mol Biol; 2008 Feb; 376(2):582-96. PubMed ID: 18158160
[TBL] [Abstract][Full Text] [Related]
6. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
7. PrP N-terminal domain triggers PrP(Sc)-like aggregation of Dpl.
Erlich P; Cesbron JY; Lemaire-Vieille C; Curt A; Andrieu JP; Schoehn G; Jamin M; Gagnon J
Biochem Biophys Res Commun; 2008 Jan; 365(3):478-83. PubMed ID: 17997980
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of prion inhibition by phenothiazine compounds.
Baral PK; Swayampakula M; Rout MK; Kav NN; Spyracopoulos L; Aguzzi A; James MN
Structure; 2014 Feb; 22(2):291-303. PubMed ID: 24373770
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into alternate aggregated prion protein forms.
Polano M; Bek A; Benetti F; Lazzarino M; Legname G
J Mol Biol; 2009 Nov; 393(5):1033-42. PubMed ID: 19720066
[TBL] [Abstract][Full Text] [Related]
10. Chaperonin-mediated de novo generation of prion protein aggregates.
Stöckel J; Hartl FU
J Mol Biol; 2001 Nov; 313(4):861-72. PubMed ID: 11697909
[TBL] [Abstract][Full Text] [Related]
11. Rapid formation of amyloid from alpha-monomeric recombinant human PrP in vitro.
Tahiri-Alaoui A; James W
Protein Sci; 2005 Apr; 14(4):942-7. PubMed ID: 15741327
[TBL] [Abstract][Full Text] [Related]
12. Seeded conversion of recombinant prion protein to a disulfide-bonded oligomer by a reduction-oxidation process.
Lee S; Eisenberg D
Nat Struct Biol; 2003 Sep; 10(9):725-30. PubMed ID: 12897768
[TBL] [Abstract][Full Text] [Related]
13. Monitoring prion protein stability by NMR.
Julien O; Graether SP; Sykes BD
J Toxicol Environ Health A; 2009; 72(17-18):1069-74. PubMed ID: 19697241
[TBL] [Abstract][Full Text] [Related]
14. Prion protein oligomer and its neurotoxicity.
Huang P; Lian F; Wen Y; Guo C; Lin D
Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):442-51. PubMed ID: 23557632
[TBL] [Abstract][Full Text] [Related]
15. Effects of detergents on the secondary structures of prion protein peptides as studied by CD spectroscopy.
Kuroda Y; Maeda Y; Sawa S; Shibata K; Miyamoto K; Nakagawa T
J Pept Sci; 2003 Apr; 9(4):212-20. PubMed ID: 12725242
[TBL] [Abstract][Full Text] [Related]
16. Structural intermediates in the putative pathway from the cellular prion protein to the pathogenic form.
Jansen K; Schäfer O; Birkmann E; Post K; Serban H; Prusiner SB; Riesner D
Biol Chem; 2001 Apr; 382(4):683-91. PubMed ID: 11405232
[TBL] [Abstract][Full Text] [Related]
17. Peptide NMHRYPNQ of the cellular prion protein (PrP(C)) inhibits aggregation and is a potential key for understanding prion-prion interactions.
Rehders D; Claasen B; Redecke L; Buschke A; Reibe C; Jehmlich N; von Bergen M; Betzel C; Meyer B
J Mol Biol; 2009 Sep; 392(1):198-207. PubMed ID: 19607841
[TBL] [Abstract][Full Text] [Related]
18. Intriguing nucleic-acid-binding features of mammalian prion protein.
Silva JL; Lima LM; Foguel D; Cordeiro Y
Trends Biochem Sci; 2008 Mar; 33(3):132-40. PubMed ID: 18243708
[TBL] [Abstract][Full Text] [Related]
19. Structural insights into the interaction between prion protein and nucleic acid.
Lima LM; Cordeiro Y; Tinoco LW; Marques AF; Oliveira CL; Sampath S; Kodali R; Choi G; Foguel D; Torriani I; Caughey B; Silva JL
Biochemistry; 2006 Aug; 45(30):9180-7. PubMed ID: 16866364
[TBL] [Abstract][Full Text] [Related]
20. Prion protein alpha-to-beta transition monitored by time-resolved Fourier transform infrared spectroscopy.
Ollesch J; Künnemann E; Glockshuber R; Gerwert K
Appl Spectrosc; 2007 Oct; 61(10):1025-31. PubMed ID: 17958950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
